Linc-ROR also serves as an oncogenic lncRNA in breast cancer and promotes the survival of breast cancer cells during rapamycin treatment by functioning as a ceRNA for miR-194-3p, which targets MECP2 [20]. This evidence concerns the gene MECP2 and breast carcinoma.